| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5bc5292a07e34d16eb1d033a16d3aec3 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-06 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-006
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-727
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-727
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-60 |
| filingDate |
2021-02-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1917da2f3eede4017741b64f2febe93c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_87f9759755d8edb9a27b6dce6d2a8a4c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f04ebbcd78db249c5b9973ab62447611
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_84077e773060412df63d7e371bcfdd03
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4ae27ccf7683a319c4e82f395e75c6e8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9e48362738e166e02bd43b32cf0a9d79 |
| publicationDate |
2022-10-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20220143016-A |
| titleOfInvention |
High molecular weight heparin compositions and methods for diagnosis, treatment and monitoring of eosinophil-mediated inflammatory diseases |
| abstract |
Disclosed herein are compositions comprising high molecular weight heparin. The composition comprises an effective amount of a high molecular weight heparin having an average molecular weight of from about 20 kDa to about 40 kDa and having a purity of at least 50%, and a pharmaceutically acceptable excipient. Also disclosed herein are methods of treating eosinophil-associated inflammation in a subject. |
| priorityDate |
2020-02-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |